The 2024 China Brand Value Ranking Released: Yichang Renfu Pharmaceutical’s Brand Value Hits a New High Again

Release time:

2024-06-21 09:50

Source:

Recently, Xinhua News Agency, the China Brand Building Promotion Association, the China Asset Appraisal Association, and other organizations jointly released the “2024 China Brand Value Evaluation Information.” Yichang Renfu Pharmaceutical ranked ninth in the pharmaceutical and healthcare category, with a brand value of 11.542 billion yuan—a rise of over 20% compared to the previous year.

The “China Brand Value Evaluation Information Release” has been held continuously for 11 years and represents an important initiative for establishing a brand value evaluation mechanism with Chinese characteristics, fostering positive energy for Chinese brands, and promoting the global reach of Chinese brands. This year, the number of brands participating in the evaluation reached 1,034, covering leading enterprises from most major industries.

Yichang Renfu Pharmaceutical has participated in the brand value assessment for five consecutive years, and this year its brand value increased by 2 billion yuan compared to the previous year. Recently, the Hubei Province Brand Development Promotion Association also released, for the first time, a ranking of industry-wide brand values across all sectors within Hubei Province. Yichang Renfu Pharmaceutical ranked 14th among all industries and first among pharmaceutical manufacturing enterprises, leading the rankings in its specific sub-sector. This clearly demonstrates the company’s remarkable achievements in fostering new-quality productivity and driving high-quality development.

China Brand Value Ranking: Yichang Renfu Hits a New High

Yichang Renfu Pharmaceutical’s Brilintec tablets have been approved for clinical trials.

Yichang Renfu Pharmaceutical’s oxycodone hydrochloride extended-release tablets have been approved for a new 10mg dosage strength.

Trending News

Accelerating the layout for independent production of innovative drugs: The construction of Renfu Pharmaceutical’s innovative drug industrial base has begun.

Yichang Renfu Pharmaceutical’s Bupropion Hydrochloride Extended-Release Tablets (XL) Approved for Marketing in Canada

Yichang Renfu Pharmaceutical has been selected as an Excellence-Level Smart Factory for 2025.

Yichang Renfu Pharmaceutical won second and third prizes in the finals of the China Innovation Methods Competition.

Deng Renjie Conducts a Survey of Renfu Pharmaceutical

Tide of Innovation and Entrepreneurship, Pursuing Dreams Together | The 22nd Corporate Day of China Merchants Group and the 2025 Employee Badminton and Basketball Tournament of Renfu Pharmaceutical Were Successfully Held.

Corporate culture

Make drug launches safer and faster, and ensure the tree of life remains evergreen.